Differential Perspectives by Specialty on Oligometastatic Colorectal Cancer: A Korean-Oligometastasis Working Group’s Comparative Survey Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Despite numerous studies on the optimal treatments for oligometastatic disease (OMD), there is no established interdisciplinary consensus on its diagnosis or classification. This survey-based study aimed to analyze the differential opinions of colorectal surgeons and radiation oncologists regarding the definition and treatment of OMD from the colorectal primary. Materials and Methods A total of 141 participants were included in this study, consisting of 63 radiation oncologists (44.7%) and 78 colorectal surgeons (55.3%). The survey consisted of 19 questions related to OMD, and the responses were analyzed using the chi-square test to determine statistical differences between the specialties. Results The radiation oncologists chose “bone” more frequently compared to the colorectal surgeons (19.2% vs. 36.5%, p=0.022), while colorectal surgeons favored “peritoneal seeding” (26.9% vs. 9.5%, p=0.009). Regarding the number of metastatic tumors, 48.3% of colorectal surgeons responded that “irrelevant, if all metastatic lesions are amendable to local therapy”, while only 21.8% of radiation oncologist chose same answer. When asked about molecular diagnosis, most surgeons (74.8%) said it was important, but only 35.8% of radiation oncologists agreed. Conclusion This study demonstrates that although radiation oncologists and colorectal surgeons agreed on a majority of aspects such as diagnostic imaging, biomarker, systemic therapy, and optimal timing of OMD, they also had quite different perspectives on several aspects of OMD. Understanding these differences is crucial to achieving multidisciplinary consensus on the definition and optimal management of OMD.
Abstract
Purpose Despite numerous studies on the optimal treatments for oligometastatic disease (OMD), there is no established interdisciplinary consensus on its diagnosis or classification. This survey-based study aimed to analyze the differential opinions of colorectal surgeons and radiation oncologists regarding the definition and treatment of OMD from the colorectal primary. Materials and Methods A total of 141 participants were included in this study, consisting of 63 radiation oncologists (44.7%) and 78 colorectal surgeons (55.3%). The survey consisted of 19 questions related to OMD, and the responses were analyzed using the chi-square test to determine statistical differences between the specialties. Results The radiation oncologists chose “bone” more frequently compared to the colorectal surgeons (19.2% vs. 36.5%, p=0.022), while colorectal surgeons favored “peritoneal seeding” (26.9% vs. 9.5%, p=0.009). Regarding the number of metastatic tumors, 48.3% of colorectal surgeons responded that “irrelevant, if all metastatic lesions are amendable to local therapy”, while only 21.8% of radiation oncologist chose same answer. When asked about molecular diagnosis, most surgeons (74.8%) said it was important, but only 35.8% of radiation oncologists agreed. Conclusion This study demonstrates that although radiation oncologists and colorectal surgeons agreed on a majority of aspects such as diagnostic imaging, biomarker, systemic therapy, and optimal timing of OMD, they also had quite different perspectives on several aspects of OMD. Understanding these differences is crucial to achieving multidisciplinary consensus on the definition and optimal management of OMD.
참고문헌 (30)
- Hellman S, "Oligometastases", J Clin Oncol, 13, pp.8~10 (1995)
- Choti MA, "Trends in long-term survival following liver resection for hepatic colorectal metastases", Ann Surg, 235, pp.759~766 (2002)
- Kanas GP, "Survival after liver resection in metastatic colorectal cancer : review and meta-analysis of prognostic factors", Clin Epidemiol, 4, pp.283~301 (2012)
- Guckenberger M, "Characterisation and classification of oligometastatic disease : a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation", Lancet Oncol, 21, pp.e18~28 (2020)
- Willmann J, "Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy : a retrospective single center study", Radiother Oncol, 168, pp.256~264 (2022)
- Xi Y, "Global colorectal cancer burden in 2020 and projections to 2040", Transl Oncol, 14, pp.101174~ (2021)
- Hughes KS, "Resection of the liver for colorectal carcinoma metastases : a multi-institutional study of long-term survivors", Dis Colon Rectum, 31, pp.1~4 (1988)
- Pastorino U, "Long-term results of lung metastasectomy : prognostic analyses based on 5206 cases", J Thorac Cardiovasc Surg, 113, pp.37~49 (1997)
- Nordlinger B, "Surgical resection of colorectal carcinoma metastases to the liver : a prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie", Cancer, 77, pp.1254~1262 (1996)
- Shida D, "Factors affecting R0 resection of colorectal cancer with synchronous peritoneal metastases : a multicenter prospective observational study by the Japanese Society for Cancer of the Colon and Rectum", Int J Clin Oncol, 25, pp.330~337 (2020)
- Santini D, "Natural history of bone metastasis in colorectal cancer : final results of a large Italian bone metastases study", Ann Oncol, 23, pp.2072~2077 (2012)
- Christensen TD, "Systematic review : incidence, risk factors, survival and treatment of bone metastases from colorectal cancer", J Bone Oncol, 13, pp.97~105 (2018)
- Van Cutsem E, "ESMO consensus guidelines for the management of patients with metastatic colorectal cancer", Ann Oncol, 27, pp.1386~1422 (2016)
- O’Cathail SM, "Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy", Radiother Oncol, 151, pp.280~286 (2020)
- Kalapurackal Mathai V, "Outcomes of isolated distant lymph node metastases in colorectal cancer", J Clin Oncol, 39(3 Suppl), pp.84~ (2021)
- Lievens Y, "Defining oligometastatic disease from a radiation oncology perspective : an ESTRO-ASTRO consensus document", Radiother Oncol, 148, pp.157~166 (2020)
- Fong Y, "Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer : analysis of 1001 consecutive cases", Ann Surg, 230, pp.309~318 (1999)
- 김기열, "Novel Methods for Clinical Risk Stratification in Patients with Colorectal Liver Metastases", Cancer Research and Treatment, 47(2), pp.242~250 (2015), 대한암학회[DOI]
- Taieb J, "Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab : a post hoc analysis of the PETACC-8 trial", JAMA Oncol, 2, pp.643~653 (2016)
- Tan C, "KRAS mutation testing in metastatic colorectal cancer", World J Gastroenterol, 18, pp.5171~5180 (2012)
- Vaughn CP, "Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer", Genes Chromosomes Cancer, 50, pp.307~312 (2011)
- Li Y, "Analysis of KRAS, NRAS, and BRAF mutations, microsatellite instability, and relevant prognosis effects in patients with early colorectal cancer : a cohort study in East Asia", Front Oncol, 12, pp.897548~ (2022)
- Singh MP, "Molecular subtypes of colorectal cancer : An emerging therapeutic opportunity for personalized medicine", Genes Dis, 8, pp.133~145 (2021)
- Pitroda SP, "Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis", Nat Commun, 9, pp.1793~ (2018)
- Jethwa KR, "Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer", Radiother Oncol, 146, pp.29~36 (2020)
- Hong TS, "Phase II study of proton-based stereotactic body radiation therapy for liver metastases : importance of tumor genotype", J Natl Cancer Inst, 109, pp.djx031~ (2017)
- Bongkot Jia-Mahasap, "Stereotactic radiosurgery for limited brain metastasis using three different techniques: helical tomotherapy, volumetric modulated arc therapy, and cone-based LINAC radiosurgery", Radiation oncology journal, 40(4), pp.232~241 (2022), 대한방사선종양학회
- Tsai CJ, "Final analysis of consolidative use of radiotherapy to block(CURB)oligoprogression trial : a randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers", Int J Radiat Oncol Biol Phys, 114, pp.P1061~ (2022)
- Chmura SJ, "NRG-BR002 : a phase IIR", III trial of standard of care systemic therapy with or without stereotactic body radiotherapy(SBRT)and, J Clin Oncol, pp.2022, 40(16 Suppl)[DOI]
- 장원일, "Clinical utilization of radiation therapy in Korea between 2017 and 2019", Radiation oncology journal, 40(4), pp.251~259 (2022), 대한방사선종양학회